Chee Ryan C H, Lin Norman H, Ho Jamie S Y, Leow Aloysius S T, Li Tony Y W, Lee Edward C Y, Chan Mark Y, Kong William K F, Yeo Tiong-Cheng, Chai Ping, Yip James W L, Poh Kian-Keong, Sharma Vijay K, Yeo Leonard L L, Tan Benjamin Y Q, Sia Ching-Hui
Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore.
Department of Cardiology, National University Heart Centre Singapore, Singapore 119074, Singapore.
J Cardiovasc Dev Dis. 2023 May 25;10(6):231. doi: 10.3390/jcdd10060231.
(1) Background: Little is known about how left ventricular systolic dysfunction (LVSD) affects functional and clinical outcomes in acute ischemic stroke (AIS) patients undergoing thrombolysis; (2) Methods: A retrospective observational study conducted between 2006 and 2018 included 937 consecutive AIS patients undergoing thrombolysis. LVSD was defined as left ventricular ejection fraction (LVEF) < 50%. Univariate and multivariate binary logistic regression analysis was performed for demographic characteristics. Ordinal shift regression was used for functional modified Rankin Scale (mRS) outcome at 3 months. Survival analysis of mortality, heart failure (HF) admission, myocardial infarction (MI) and stroke/transient ischemic attack (TIA) was evaluated with a Cox-proportional hazards model; (3) Results: LVSD patients in comparison with LVEF ≥ 50% patients accounted for 190 and 747 patients, respectively. LVSD patients had more comorbidities including diabetes mellitus (100 (52.6%) vs. 280 (37.5%), < 0.001), atrial fibrillation (69 (36.3%) vs. 212 (28.4%), = 0.033), ischemic heart disease (130 (68.4%) vs. 145 (19.4%), < 0.001) and HF (150 (78.9%) vs. 46 (6.2%), < 0.001). LVSD was associated with worse functional mRS outcomes at 3 months (adjusted OR 1.41, 95% CI 1.03-1.92, = 0.030). Survival analysis identified LVSD to significantly predict all-cause mortality (adjusted HR [aHR] 3.38, 95% CI 1.74-6.54, < 0.001), subsequent HF admission (aHR 4.23, 95% CI 2.17-8.26, < 0.001) and MI (aHR 2.49, 95% CI 1.44-4.32, = 0.001). LVSD did not predict recurrent stroke/TIA (aHR 1.15, 95% CI 0.77-1.72, = 0.496); (4) Conclusions: LVSD in AIS patients undergoing thrombolysis was associated with increased all-cause mortality, subsequent HF admission, subsequent MI and poorer functional outcomes, highlighting a need to optimize LVEF.
(1)背景:对于左心室收缩功能障碍(LVSD)如何影响接受溶栓治疗的急性缺血性卒中(AIS)患者的功能和临床结局,人们了解甚少;(2)方法:一项回顾性观察性研究纳入了2006年至2018年间连续接受溶栓治疗的937例AIS患者。LVSD定义为左心室射血分数(LVEF)<50%。对人口统计学特征进行单因素和多因素二元逻辑回归分析。采用有序移位回归分析3个月时的功能改良Rankin量表(mRS)结局。用Cox比例风险模型评估死亡率、心力衰竭(HF)住院、心肌梗死(MI)和卒中/短暂性脑缺血发作(TIA)的生存分析;(3)结果:LVSD患者和LVEF≥50%的患者分别为190例和747例。LVSD患者有更多的合并症,包括糖尿病(100例(52.6%)对280例(37.5%),P<0.001)、心房颤动(69例(36.3%)对212例(28.4%),P = 0.033)、缺血性心脏病(130例(68.4%)对145例(19.4%),P<0.001)和HF(150例(78.9%)对46例(6.2%),P<0.001)。LVSD与3个月时较差的功能mRS结局相关(校正OR 1.41,95%CI 1.03 - 1.92,P = 0.030)。生存分析确定LVSD可显著预测全因死亡率(校正HR [aHR] 3.38,95%CI 1.74 - 6.54,P<0.001)、随后的HF住院(aHR 4.23,95%CI 2.17 - 8.26,P<0.001)和MI(aHR 2.49,95%CI 1.44 - 4.32,P = 0.001)。LVSD不能预测复发性卒中/TIA(aHR 1.15,95%CI 0.77 - 1.72,P = 0.496);(4)结论:接受溶栓治疗的AIS患者中的LVSD与全因死亡率增加、随后的HF住院、随后的MI以及较差的功能结局相关,突出了优化LVEF的必要性。